Scotiabank analyst Sung Ji Nam lowered the firm’s price target on Quanterix (QTRX) to $18 from $28 and keeps an Outperform rating on the shares. Despite the relatively stronger revenue growth performance compared to its peer group, the company’s shares underperformed over the last year, the analyst tells investors. While the firm thinks the operating synergy targets are reasonable, it is less certain about the top line growth potential.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX:
- Quanterix’s Earnings Call: Growth Amid Challenges
- Quanterix price target lowered to $10 from $11 at TD Cowen
- Buy Rating Affirmed for Quanterix Amid Strong Q4 Performance and Strategic Merger with Akoya Biosciences
- Quanterix price target lowered to $15 from $20 at Canaccord
- Quanterix Reports Strong Revenue Growth and Strategic Expansion